Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Equal Weight Rating from Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note published on Friday morning, MarketBeat reports. The brokerage issued an equal weight rating and a $55.00 price objective on the stock.

AMPH has been the topic of a number of other research reports. Piper Sandler lowered their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $60.33.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $44.64 on Friday. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 15.15, a price-to-earnings-growth ratio of 0.90 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals has a one year low of $36.56 and a one year high of $65.92. The stock’s fifty day moving average is $48.26 and its 200-day moving average is $44.47.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The trade was a 3.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William J. Peters sold 7,426 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,898,061.15. This represents a 7.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,533 shares of company stock valued at $1,378,252 in the last three months. 27.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. TD Asset Management Inc grew its holdings in shares of Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after buying an additional 680,976 shares in the last quarter. Boston Trust Walden Corp acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $26,189,000. Millennium Management LLC grew its stake in Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after acquiring an additional 338,653 shares in the last quarter. Epoch Investment Partners Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth approximately $9,085,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.